United Therapeutics Corporation

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 16/06/2025 BST			5-day change	1st Jan Change
288.56 ^USD	+1.84%		-11.44%	-18.22%

06-16	United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing	MT
06-10	Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints	MT

Tempus, United Therapeutics Launch Collaboration to Use AI to Detect Risk of Pulmonary Hypertension

Published on 25/06/2024 at 15:22, updated on 25/06/2024 at 15:45

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about United Therapeutics Corporation

United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing	06-16	MT
Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints	06-10	MT
Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial	06-10	RE
Liquidia, United Therapeutics Shares Fall Pre-Bell After Rival Insmed's Phase 2b PAH Trial Meets Endpoints	06-10	MT
Liquidia Set to Make First Commercial Shipment of Yutrepia for Pulmonary Hypertension	06-02	MT
Cantor Fitzgerald Initiates United Therapeutics at Overweight With $405 Price Target	06-02	MT
Liquidia Receives FDA Approval on Yutrepia for Treatment of Pulmonary Hypertension	05-23	MT
Liquidia Faces Patent Litigation Filed by United Therapeutics	05-12	MT
Liquidia Says New Litigation Filed Against Co In U.S.	05-12	RE
United Therapeutics Corporation, Q1 2025 Earnings Call, Apr 30, 2025	04-30
United Therapeutics Q1 Earnings, Revenue Rise	04-30	MT
Earnings Flash (UTHR) United Therapeutics Posts Q1 Revenue $794.4M, vs. FactSet Est of $729.3M	04-30	MT
United Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	04-30	CI
United Therapeutics Enters Credit Agreement With Wells Fargo - SEC Filing	04-28	RE
United Therapeutics Corporation Announces Credit Agreement Established for A $2.5 Billion Revolving Facility	04-28	CI
Liquidia Corp Unit Files Patent Infringement Action Against United Therapeutics	04-22	RE
BofA Securities Upgrades United Therapeutics to Neutral From Underperform	04-21	MT
United Therapeutics Insider Sold Shares Worth $3,121,543, According to a Recent SEC Filing	04-21	MT
United Therapeutics Insider Sold Shares Worth $1,138,200, According to a Recent SEC Filing	04-08	MT
United Therapeutics Insider Sold Shares Worth $3,367,984, According to a Recent SEC Filing	04-07	MT
United Therapeutics Insider Sold Shares Worth $796,991, According to a Recent SEC Filing	03-25	MT
UBS Adjusts Price Target on United Therapeutics to $410 From $440, Maintains Buy Rating	03-18	MT
United Therapeutics Corporation Presents at Leerink?s Global Healthcare Conference 2025, Mar-11-2025 10:00 AM	03-11
United Therapeutics Corporation Presents at TD Cowen 45th Annual Healthcare Conference, Mar-03-2025 01:50 PM	03-03
Stocks in motion: Intuit and Axon rise on great results, Applovin tumbles on short-seller attack	02-26

Chart United Therapeutics Corporation

Duration

Period

UTHR: Dynamic Chart

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Employees

1,305

Sector

Pharmaceuticals

Calendar

06-26 - Annual General Meeting

More about the company